Eylward Susan sold $4K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 2,541 shares of Imunon, Inc. (IMNN) at $1.57 on 2026-08-03.

Original reporting
SEC EDGAR · Eylward Susan
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 3:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The disclosure updates the record of insider selling activity but does not introduce new operational or financial information about Imunon.

02

Market read

Traders may monitor IMNN for follow-on insider activity, but this filing alone is unlikely to change valuation drivers.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide total insider ownership changes beyond the post-transaction share count.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-04, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon, Inc. disclosed a Form 4 showing General Counsel Eylward Susan sold 2,541 shares at $1.5651 on 2026-08-03.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment rather than fundamentals.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but it provides no new company performance, guidance, or deal information. The sale size is modest and the article lacks context on motivations or broader insider activity.

Market effects

No sector-level signal; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification or tax needs and may not reflect negative expectations, especially without any accompanying negative company news.

Key entities

  • Imunon, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Eylward Susan

    General Counsel and Corp Sec who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.